Breaking News

Polyplus Introduces LipidBrick for LNP Formulation in mRNA Therapeutics

LipidBrick IM21.7c broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications.

Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, introduced a novel cationic lipid for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. LipidBrick IM21.7c, broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications. LipidBrick IM21.7c overcomes current generation ionizable lipid challenges used in LNP’s, by enabling ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters